MULTICENTRIC, OPEN, RANDOMIZED, COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TELITROMYCIN 800 MG VIA ORAL ONCE A DAY FOR 5 DAYS VS. AMOXICILLINE / CLAVULIC ACID 500/125 MG VIA ORAL THREE TIMES A DAY FOR 10 DAYS IN THE TREATMENT OF ACUTE MAXILAR SYNTHETIS OR MAXILAR-ACUTE ETHIOIDAL IN ADULTS.
Not Applicable
- Conditions
- -J010 Acute maxillary sinusitisAcute maxillary sinusitisJ010
- Registration Number
- PER-040-02
- Lead Sponsor
- AVENTIS PHARMA S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Be 18 years old and have a diagnosis of acute maxillary sinusitis or
acute maxillary-ethmoidal uncomplicated.
Exclusion Criteria
Patients who have had at least 3 episodes of maxillary sinusitis
acute or maxilar-ethmoidal acute in the last 12 months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Telitromycin's efficacy in treating acute maxillary sinusitis compared to amoxicillin/clavulanate?
How does the 5-day Telitromycin regimen compare to 10-day amoxicillin/clavulanate in clinical outcomes for J010 acute maxillary sinusitis?
Are there biomarkers predictive of response to Telitromycin versus amoxicillin/clavulanate in maxillary-acute ethmoidal sinusitis?
What adverse event profiles and management strategies were observed in PER-040-02 for Telitromycin and amoxicillin/clavulanate regimens?
How do ketolides like Telitromycin and beta-lactam/beta-lactamase inhibitors compare in treating bacterial sinusitis subtypes (J010)?